Author

R. Herrup

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 3 Organism:human· 2 Assay:proteomics· 2 Approach:biophysical modeling· 1 Research Focus:cell-cell communication· 1 Research Focus:drug response / drug discovery· 1 Organism:mouse· 1

Frequent Co-Authors

S. N. Neerukonda· 3 shared C. D. Weiss· 2 shared R. Vassell· 2 shared S. Lusvarghi· 2 shared W. Wang· 2 shared A. Abdelgawad· 1 shared A. Bosshart· 1 shared A. Cornelius· 1 shared

Activity by Year

2020-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

S. N. Neerukonda

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Key substitutions in the spike protein of SARS-CoV-2 variants can predict resistance to monoclonal antibodies, but other substitutions can modify the effects

S. Lusvarghi, W. Wang, R. Herrup, S. N. Neerukonda, R. Vassell, L. Bentley, A. E. Eakin, K. J. Erlandson, C. D. Weiss

The paper evaluates resistance of 25 therapeutic antibodies to SARS-CoV-2 variants with multiple spike substitutions, finding key substitutions predict resistance but other substitutions can modify it unpredictably.

bioRxiv · Jul 16, 2021Microbiology

Ensovibep, a novel trispecific DARPin candidate that protects against SARS-CoV-2 variants

S. Rothenberger, D. L. Hurdiss, M. Walser, F. Malvezzi, J. Mayor, S. Ryter, H. Moreno, N. Liechti, A. Bosshart, C. Iss, V. Calabro, A. Cornelius, T. Hospodarsch, A. Neculcea, T. Looser, , Vassell

This paper describes ensovibep, a trispecific DARPin that inhibits SARS-CoV-2 variants by targeting the spike protein, showing potent antiviral activity and protection in animal models.

bioRxiv · Feb 3, 2021 · PreprintImmunology

Establishment of a well-characterized SARS-CoV-2 lentiviral pseudovirus neutralization assay using 293T cells with stable expression of ACE2 and TMPRSS2

S. N. Neerukonda, R. Vassell, R. Herrup, S. Liu, T. Wang, K. Takeda, Y. Yang, T.-L. Lin, W. Wang, C. D. Weiss

The paper establishes a SARS-CoV-2 lentiviral pseudovirus neutralization assay using 293T cells expressing ACE2 and TMPRSS2, showing good correlation with other assays.

bioRxiv · Dec 26, 2020Microbiology